Positive interferon-γ release assaya rate during the study
| IGRA test time | SB2 (N=290) | INF (N=293) | ||
|---|---|---|---|---|
| Positive IGRA | Seroconversionb | Positive IGRA | Seroconversionb | |
| n (%) | n (%) | n (%) | n (%) | |
| Screeningc | 19 (6.6%) | 27 (9.2%) | ||
| Week 22 | 28 (9.7%) | 19 (6.6%) | 36 (12.3%) | 20 (6.8%) |
| Week 54 or early termination | 26 (9.0%) | 7 (2.4%) | 24 (8.2%) | 7 (2.4%) |
aPatients, whose first and second interferon-γ release assay results were indeterminate, were considered to have the positive IGRA (at Screening 1 patient in each SB2 and INF; at Week 22, 4 patients in SB2 and 5 patients in INF for both positive IGRA and seronconversion; at Week 54, no patient in each SB2 and INF). bSeroconversion defined as negative to positive test change at each test time. cRandomised patients only.